Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-1.82% $10.80
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 70.24 mill |
EPS: | -24.00 |
P/E: | -0.450 |
Earnings Date: | May 09, 2024 |
SharesOutstanding: | 6.50 mill |
Avg Daily Volume: | 0.0321 mill |
RATING 2024-03-28 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Buy | |
P/E: | Sell | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | |||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.450 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.08x |
Company: PE -0.450 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 10.30 - 11.30 ( +/- 4.63%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-10 | Laumas Sandeep | Buy | 80 000 | Employee Stock Option (right to buy) |
2024-02-10 | Crouch Bronson | Buy | 120 000 | Employee Stock Option (right to buy) |
2023-06-14 | Binder Gwendolyn | Buy | 1 500 | Stock Option (Right to Buy) |
2023-06-14 | Mcgaughy R Kent Jr | Buy | 1 500 | Stock Option (Right to Buy) |
2023-06-14 | Gibson Neil W | Buy | 1 500 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
94.50 |
Last 92 transactions |
Buy: 125 955 560 | Sell: 140 779 900 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $10.80 (-1.82% ) |
Volume | 0.0130 mill |
Avg. Vol. | 0.0321 mill |
% of Avg. Vol | 40.56 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.